

24 Sartorius, N., Baghai, T.C., Baldwin, D.S., et al. 2007. Antidepressant Medications and Other Treatments of Depressive Disorders: A CINP Task Force Report Based on a Review of Evidence. The International Journal of Neuropsychopharmacology. 10(s1):s1-207.

Table 22. Published placebo-controlled RCTs of SSRIs and newer antidepressants in children and adolescents (relevant excerpt)

Agent	Author	N	Age	Dose (mg)	Length (weeks)	Sites (n)	Primary Outcome	Active Treatment	Placebo	P value	Sig? (Y/N)	Sponsor
Paroxetine	Keller et al. 2001	180**	12-18	20-40	8	10	HAMD \leq 8 or decreased by \geq 50%	66.5%	55.2%	0.11	N	GSK
							HAMD (cfb)	18.98 to 8.24	19.79 to 9.88	0.13	N	

** Trial included 275 subjects, but 95 were randomized to imipramine and are not considered in the above analysis.

cfb=change from baseline; cts=change in total score (adjusted mean); n.a.=not available; GSK=GlaxoSmithKline.